| Source: |
| Type: |
| SUV39H1/KMT1A (suppressor of variegation 3-9 homolog 1; H3K9 histone methyltransferase) is a SET-domain lysine methyltransferase that catalyzes methylation of histone H3 lysine 9, particularly formation of H3K9me3, a repressive chromatin mark associated with heterochromatin and transcriptional silencing. SUV39H1 regulates chromatin organization, genome stability, cellular differentiation, senescence and gene expression. In several cancers, increased SUV39H1 activity can promote epigenetic silencing of tumour-suppressive genes, stemness, proliferation and treatment resistance, although its role can vary by tumour context. In such settings, the cancer-associated direction is commonly up and the desired anticancer modulation is down or methyltransferase inhibition. |
| Osteosarcoma is a type of cancer that starts in the bones. It is the most common type of bone cancer, and it usually affects children and young adults, although it can occur at any age. Osteosarcoma typically develops in the long bones of the body, such as the arms and legs, but it can also occur in other bones, including the pelvis and jaw. |
| 7174- | CHA, | Inhibition of SUV39H1 reduces tumor angiogenesis via Notch1 in oral squamous cell carcinoma |
| - | vitro+vivo, | OS, | OS-RC-2 |
| 7163- | CHA, | The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | OS, | U2OS | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HeLa | - | in-vivo, | Ovarian, | SKOV3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:46 Cells:% prod#:% Target#:1592 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid